A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

NCT00249808 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1266

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Efalizumab - anti-CD11a recombinant human monoclonal antibody

Sponsor

Merck KGaA, Darmstadt, Germany